805 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Recruiting A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: CC-122
22 Recruiting GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Obinutuzumab and Pixantrone
23 Not yet recruiting Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Cytokine-induced killer cells (CIK)
24 Recruiting A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Lymphoma, Follicular;   Cancer;   Neoplasm;   Tumor;   Lymphoma, Malignant;   Lymphoma, B-cell;   Lymphoma, Non-Hodgkin
Interventions: Drug: ASN002 Dose Escalation;   Drug: ASN002 MTD
25 Not yet recruiting Symbenda Post-Marketing Surveillance (PMS)
Conditions: Lymphoma, Non-Hodgkin;   Lymphocytic Leukemia;   Multiple Myeloma
Intervention:
26 Recruiting ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: ESHAP-Imatinib
27 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
28 Recruiting Molecular and Whole-body MR Imaging in Lymphomas
Conditions: Lymphoma;   Hodgkin Disease;   Lymphoma, Non-Hodgkin
Intervention: Other: 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
29 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
30 Not yet recruiting Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
Interventions: Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
31 Recruiting Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
32 Recruiting Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Conditions: Multiple Myeloma;   Lymphoma, Non-Hodgkin
Interventions: Drug: XM02 Filgrastim;   Drug: Filgrastim;   Procedure: Apheresis;   Drug: Plerixafor
33 Recruiting Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Leukemia Acute Myeloid;   Lymphoma, Non-Hodgkin;   Myelodysplastic Syndrome;   Immunologic Deficiency Syndromes
Interventions: Biological: BPX-501 T cells and AP1903;   Drug: AP1903
34 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
35 Recruiting Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Conditions: MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention: Device: Graft Manipulation (CD34+ Selection)
36 Unknown  Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
37 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
38 Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: SD-101;   Radiation: Local Radiation
39 Recruiting Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Hematopoetic Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention: Drug: Sitagliptin
40 Recruiting Tissue Collection for Studies of Lymph Cancer
Conditions: Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years